The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Although a large number of economic analyses of allergic rhinitis have been published, there are relatively few empirically based studies, particularly outside the US. The majority of these analyses can be classified as burden-of-illness studies. Most estimates of the annual cost of allergic rhinitis range from dollars US 2-5 billion (2003 values). The wide range of estimates can be attributed to differences in identifying patients with allergic rhinitis, differences in cost assignment, limitations associated with available data and difficulties in assigning indirect costs (associated with reduced productivity) of allergic rhinitis. Approximately one-third of burden-of-illness studies include direct and indirect costs of allergic rhinitis, about one-third focus on direct costs only, and the remaining one-third focus exclusively on indirect costs due to reduced productivity. Indirect costs attributable to allergic rhinitis were higher in studies only estimating indirect costs (dollars US 5.5-9.7 billion) than in those estimating both direct and indirect costs (dollars US 1.7-4.3 billion). Although there are many economic evaluations of allergic rhinitis treatments in the published medical literature, very few represent formal cost-effectiveness evaluations that compare the incremental costs and benefits of alternative treatment strategies. Those that are incremental cost-effectiveness analyses have several limitations, including small samples, short study periods and the lack of a standardized measure of effectiveness. To date, the medical literature is lacking a comprehensive economic evaluation of general treatment strategies for allergic rhinitis. In undertaking such an analysis, serious consideration must be given to the study population of interest, the choice of appropriate comparators, the perspective from which the analysis is conducted, the target audience, the changing healthcare marketplace and the selection of a measure of effectiveness that incorporates both positive and negative aspects of treatments for allergic rhinitis. Future work would benefit from the development of a consensus on a summary measure of effectiveness that could be used in cost-effectiveness analyses of therapies for allergic rhinitis as well as additional empirical work to measure the association between severity of disease and its impact on worker productivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The total burden for AR lies not only in the impairment of physical and social functioning, but also in the financial burden, which is greater when its role in comorbid conditions such as asthma and rhinosinusitis are taken into account.754-756”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [754]
Citations
Cites
Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
JUNIPER, E. F., & GUYATT, G. H. (1991) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1991.tb00807.x · Cited by 811
Dykewicz, M. S., Fineman, S., Skoner, D. P., Nicklas, R., Lee, R., Blessing-Moore, J., Li, J. T., Bernstein, I. L., Berger, W., Spector, S., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63155-9 · Cited by 652
Weiner, J. M., Abramson, M. J., & Puy, R. M. (1998) · BMJ · doi:10.1136/bmj.317.7173.1624 · Cited by 527 · cited 1×
“Finally, we provide an inintranasal corticosteroids over antihistamines in the depth discussion of some of the methodological management of allergic rhinitis.[21-25] Clear differissues that should be addressed in order to conduct ences in clinical efficacy have not been demonstracomprehensive, high quality cost-effect…”
MethodChanging prevalence of allergic rhinitis and asthma
Sly, R. M. (1999) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62603-8 · Cited by 383
Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire☆☆☆★
Juniper, E. F., Thompson, A. K., Ferrie, P. J., & Roberts, J. N. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70380-5 · Cited by 376
A cost of illness study of allergic rhinitis in the United States
Malone, D. C., Lawson, K. A., Smith, D. H., Arrighi, H. M., & Battista, C. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70296-3 · Cited by 277
Interpretation of rhinoconjunctivitis quality of life questionnaire data
Juniper, E. F., Guyatt, G. H., Griffith, L. E., & Ferrie, P. J. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70135-5 · Cited by 244
Yáñez, A., & Rodrigo, G. J. (2002) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62085-6 · Cited by 226
Measuring health-related quality of life in rhinitis
Juniper, E. F. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)90000-2 · Cited by 221
The cost of productivity losses associated with allergic rhinitis.
Crystal-Peters, J., Crown, W. H., Goetzel, R. Z., & Schutt, D. C. (2000) · PubMed · Cited by 191
Research works printed but not linked: 14
- McMenamin, 1994, Ann Allergy, 73, 35
- Malone, 1997, J Allergy Clin Immunol, 99, 22
- Mackowiak, 1997, Am J Manag Care, 3, S8
- Ross, 1996, Am J Manag Care, 2, 285
- Crystal-Peters, 2000, Am J Manag Care, 6, 373
- Stempel, 1998, Am J Manag Care, 4, 89
- Hindmarch, 2001, Curr Med Res Opin, 17, 273, 10.1185/0300799019117014 · doi:10.1185/0300799019117014
- Yanez, 2002, Ann Allergy Asthma Immunol, 89, 479, 10.1016/S1081-1206(10)62085-6 · DOI · Paper page
- Trotter, 2000, Manag Care Interface, 13, 60
- Liao, 2001, Am J Manag Care, 7, S459
- Carvalho, 2000, Allergol Immunopathol (Madr), 28, 207
- Asher, 2001, N Z Med J, 114, 114
- Tanner, 1999, Am J Manag Care, 5, S235
- Crown, 2000, Drug Benefit Trends, 12, 5BH
Cited by
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
The global burden of mental disorders: An update from the WHO World Mental Health (WMH) surveys
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Ormel, J., Üstün, T. B., & Wang, P. S. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00001421 · Cited by 1,895
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
Brożek, J. L., Bousquet, J., Baena-Cagnani, C. E., Bonini, S., Canonica, G. W., Casale, T. B., van Wijk, R. G., Ohta, K., Zuberbier, T., & Schünemann, H. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.047 · Cited by 1,813
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Metadata
- Authors
- Reed, S. D., Lee, T. A., & McCrory, D. C.
- Affiliations
- Duke Medical Center (US)
- Northwestern University (US)
- Duke University (US)
- Corresponding author
- Reed, Shelby D
- Venue
- PharmacoEconomics
- Published
- 2004
- Volume
- 22
- Issue
- 6
- Pages
- 345-361
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W2080356144
- Semantic Scholar
- eedd242ec504bd9d0be763552df6281db061048f
- Cited by
- 222
- References
- 67
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 13 · 2022: 4 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 9 · 2016: 9 · 2015: 9 · 2014: 10 · 2013: 12 · 2012: 11
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Agency for Healthcare Research and Quality
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- allergic rhinitis, economic burden, direct costs, indirect costs, productivity loss, cost-effectiveness analysis, treatment options, disease severity, health care costs
- MeSH terms
- Histamine H1 Antagonists, Humans, Quality of Life, Rhinitis, Allergic, Perennial, United States, Cost of Illness, Economics, Pharmaceutical, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature. https://app.cochat.ai/papers/10.2165/00019053-200422060-00002
- The paper
- Reed, S. D., Lee, T. A., & McCrory, D. C. (2004). The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature. PharmacoEconomics. https://doi.org/10.2165/00019053-200422060-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.